FRANKFURT, Germany – Wanderlust and climate change mean that viruses transmitted by mosquitoes are increasingly spreading across Europe. The class of flaviviruses, which comprises the dengue, Zika, West Nile and yellow fever viruses, cause serious neurological diseases for which only insufficiently effective vaccines and no specific treatment options currently exist....
Latest News
BERLIN, Germany – Infection with the stomach bacterium Helicobacter pylori could increase the risk of developing Alzheimer’s disease: In people over the age of 50, the risk following a symptomatic infection can be an average of 11 percent higher, and even more about ten years after the infection, at 24...
NEWTON, Mass. — Inflammasome Therapeutics, a clinical-stage, private company developing a new class of inflammasome inhibitor drugs, Kamuvudines, as therapies for prevalent, degenerative diseases, announced the first patient has been dosed in a Phase 1 study of one of the company’s novel compounds in the treatment of diabetic macular edema...
Jena, Germany – InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announces positive data from the third cohort of patients in the Phase IIa open-label study with vilobelimab in Pyoderma Gangrenosum (PG). “We are happy to see more patients responding with the...
Jena, Germany – InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today the achievement of target enrollment of the Phase IIa open label study of vilobelimab in patients with Pyoderma Gangrenosum (PG). Dr. Korinna Pilz, Global Head of Clinical Research and...
Jena, Germany – InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced the initiation of the Phase III program with vilobelimab in hidradenitis suppurativa (HS) patients with active draining tunnels. The new primary endpoint, called modified HiSCR (Hidradenitis Suppurativa Clinical Response),...
Jena, Germany – InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announces its plan to proceed with a pivotal development program for vilobelimab in Hidradenitis Suppurativa (HS) after a successful Type A meeting with the US Food and Drug Administration (FDA) and...
Nantes, France — InFlectis BioScience, a pioneer in developing first-in-class therapies for neuromuscular diseases, announced that it has completed enrollment in its Phase 2 clinical trial of IFB-088 ((INN: icerguastat), a novel investigational treatment of Amyotrophic Lateral Sclerosis (ALS). “This trial reflects our commitment to bring a novel molecule with...
BOSTON, Mass. and ATLANTA, Georgia — Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease, Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced a publication of Phase 1 clinical studies with risvodetinib (“risvo”), a...
Treatment with an inhibitor of the epigenetic enzyme SETD8 may be a novel therapeutic option to overcome melphalan resistance in patients with multiple myeloma (MM), according to research published in Clinical Epigenetics. Most patients with MM eventually relapse or develop drug resistance despite treatment advances that have improved survival rates. SETD8,...